Laekna, Inc.

來凱醫藥有限公司

(Incorporated in the Cayman Islands with limited liability)

(Stock Code: 2105)

VOLUNTARY ANNOUNCEMENT

PRESENTATIONS OF CLINICAL AND PRECLINICAL STUDIES RESULTS OF LAE02, LAE03 AND LAE123 AT 2025 ADA

This announcement is made by Laekna, Inc. (the "**Company**", together with its subsidiaries, the "**Group**") on a voluntary basis to inform the shareholders and potential investors of the Company about the latest business update of the Group.

The board (the "**Board**") of directors (the "**Directors**") of the Company announces that the results of (i) phase I SAD study of LAE102 (an ActRIIA-selective antibody) for the treatment of obesity; and (ii) the pre-clinical study of LAE102, LAE103 (an ActRIIB-selective antibody) and LAE123 (an ActRIIA/IIB dual antagonistic monoclonal antibody) as therapeutics for muscle growth and fat reduction were presented at the 85th scientific sessions of the American Diabetes Association ("**ADA**").

Presentations details are as follows:

Poster No.1

Abstract Number:	2205-LB
Title:	First-in-Human Study to Evaluate Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of LAE102 in Healthy Volunteers
Time:	Sunday, June 22, 2025, 12:30 p.m.–13:30 p.m. CST
Location:	Poster Hall (Hall F1) McCormick Place Convention Center, Chicago, Illinois, the USA

Highlights:

- A total of 40 participants were enrolled in Part A (IV) and 24 participants in Part B (SC). All participants completed the study as designed. The mean age was 29.0 years and 31.2 years, with the mean BMI 23.32 kg/m^2 and 23.08 kg/m^2 in Part A and Part B, respectively. Baseline demographic and clinical characteristics were generally balanced across the intravenous ("**IV**") and subcutaneous ("**SC**") cohorts of the study.

- Overall, LAE102 was well tolerated following a single IV or SC dose. No serious adverse events or treatment emergent adverse events ("**TEAEs**") leading to discontinuation of treatment were reported. The majority of the TEAEs were mild laboratory test abnormalities, which were asymptomatic and did not require medical intervention. There was no reported case of diarrhea.

- Activin A was significantly increased in 24 hours following a single intravenous or subcutaneous dose of LAE102. The duration of Activin A elevation was dose-dependent. The high-dose groups (8 mg/kg IV group, 16 mg/kg IV group, and 8 mg/kg SC group) maintained 2-to-3-fold increases above the baseline level through 28 days post-administration, indicating prolonged pathway blocking.

- Conclusion: Single-dose administration of LAE102 by IV or SC injection demonstrated a favorable safety profile in the healthy participants. LAE102 exhibited apparent nonlinear clearance saturation at concentrations of approximately 2~4 μg/mL, a threshold that coincided with the sustained pharmacodynamics ("**PD**") effect of LAE102, maintaining Activin A levels more than 2-fold above the baseline. The robust PK/PD correlation suggests potential efficacy and supports further clinical development of LAE102 in overweight and obese populations.

Poster No.2

Abstract Number: 861-P

Title: Targeting Activin Type II Receptors — Develop Monoclonal Antibodies LAE102, LAE103, and LAE123 as Candidate Therapeutics for Muscle Growth and Fat Reduction

Time: Sunday, June 22, 2025, 12:30 p.m.–13:30 p.m. CST

Location: Poster Hall (Hall F1) McCormick Place Convention Center, Chicago, Illinois, the USA

Highlights:

- LAE102, LAE103, and LAE123 are high-affinity functional antagonists. They can completely inhibit the signaling transduced by ligands such as activin A, B, AB, and MSTN, all of which are known to contribute to muscle atrophy. In addition, they also inhibit activin E and GDF3, which promote lipid accumulation of adipose tissue.

- In mouse models, LAE102 alone significantly induced muscle growth and reduced fat mass, while LAE103 had less effect. Notably, a synergistic effect on muscle increase and fat loss was observed when combining LAE102 with LAE103, achieving the maximal effect comparable to the ActRIIA-IIB dual-specific antibody LAE123.

- Conclusion: The findings indicate that ActRIIA is a major regulator of muscle growth and fat loss in mice. LAE102 shows great potential as muscle preserving weight loss management with a favorable safety profile. On the other hand, LAE123 could be utilized to treat diseases requiring complete inhibition of both ActRIIA and ActRIIB, such as spinal muscle atrophy.

ABOUT LAE102

LAE102 is an internally discovered monoclonal antibody selectively targeting ActRIIA, a receptor that plays an important role in muscle regeneration and lipid metabolism. In the pre-clinical models, LAE102 has been shown to increase lean mass and decrease fat mass. In combination with GLP1R agonist, LAE102 can further reduce fat mass and significantly regain the lean mass loss induced by GLP1R agonist. This positions LAE102 as a promising drug candidate for achieving quality weight control.

ABOUT LAE103 AND LAE123

The Group has established a comprehensive portfolio. Among these, LAE103 (an ActRIIB-selective antibody) and LAE123 (a dual inhibitor targeting ActRIIA/IIB) have advanced to IND-enabling studies. The Group is actively advancing these drug candidates to clinical studies as novel therapies for muscle and other disease indications.

RISK WARNING

LAE102, LAE103 and LAE123 MAY NOT ULTIMATELY BE SUCCESSFULLY DEVELOPED AND COMMERCIALIZED. THE COMPANY'S SHAREHOLDERS AND POTENTIAL INVESTORS ARE REMINDED TO EXERCISE CAUTION WHEN DEALING IN THE SECURITIES OF THE COMPANY.

By Order of the Board
Laekna, Inc.
Dr. LU Chris Xiangyang
Chairman

Hong Kong, June 23, 2025

As at the date of this announcement, the Board comprises Dr. LU Chris Xiangyang, Ms. XIE Ling and Dr. GU Xiang-Ju Justin as executive Directors; Dr. WANG David Guowei and Mr. SUN Yuan as non-executive Directors; and Dr. YIN Xudong, Dr. LI Min and Mr. ZHOU Jian as independent non-executive Directors.